Endocrine Abstracts

Monotherapy with metformin is widely accepted as the second step in type 2 diabetes treatment after the failure to achieve glycemic goals with therapeutic education and lifestyle modification, including correction of diet and physical exercise habits. However, most of patients need combination therapy in first three to four years after metformin initiation. Obviously the efficacy of antidiabetic drugs used as add-on to metformin monotherapy could be different from those observ...

People with type 2 Diabetes (T2D) develop severe chronic complication early in the course of the disease if not treated optimally. Although lifestyle intervention and metformin clearly improve metabolic control with metformin having well established safety profile, both become insufficient in most patients with T2D. To achieve the current goal of HbA1c < 7% additional medication are introduced.By current recommendations, basal insulin or sulfonylurea...

Near-normoglycaemia shold be reached as safely as possible. It should be considered, that at lower HbA1c concentrations, the proportional contribution of postprandial glucose to HbA1c is greater than at higher HbA1c values.Sulfonylureas, glinides and insulin are associated with an increased risk for hypoglycaemia and weight gain. Therefore, these agents should not be considered in first line for the combination therapy in overweight patients with Type 2 ...